title: [New possibilities in the treatment of early stages of rosacea].
abstract: Rosacea is a chronic skin disease of unknown etiology, affecting the central areas of the face skin (cheeks, chin, nose, forehead) and is characterized by periods of remission and exacerbation. Currently, about 10% of the world's population suffered from rosacea. Significant role in the pathogenesis of Rosacea, most researchers reffered to vascular disorders. Pathology of the skin capillaries can be attributed with several factors, which are united by a single result - a persistent vasodilation of the skin vessels and the subsequent blood stasis. Clinically the Rosacea manifested by erythema and telangiectasia. According to Morrison (2012) in the study of the autonomic nervous system (using the vegetative index of Kerdo) the prevalence of parasympathetic tone of the autonomic nervous system has been found in Rosacea patients.  The urgency of Rosacea correction in its initial stage of development is primarily due to the state of the skin blood vessels' walls, which has not only the outward manifestation, but also influencing the trophic, morphology and function of the skin in general, the progression of the disease and its transition to a more severe stage, up to rhinophym.  Thus, it is advisable to carry out remedial measures in the early stages of Rosacea in order to correct the clinical manifestations of pre-rosacea and prevent development of more severe forms of the disease. Based on foregoing, objective of the study was to investigate the therapeutic efficacy of beta-blockers and drug Rozaliak in treatment of patients with Rosacea. We observed 25 patients (15 women and 10 men) aged 25 to 49 years with erythematous stage of Rrosacea. Depending on the treatment, all patients were divided into 2 groups. 13 patients (8 women and 5 men) were included in the control group who received a full comprehensive treatment complex, including short courses of antibiotics, systemic metronidazole, antihistamines, desensitizing agents, traditional external therapy (Rosamet, 0.75% metronidazole cream). 12 patients (7 women and 5 men) were included in the study group, which additionally, after the main course (up to the revealing of clinical effects), obtained Inderal (10 mg a day for 10-20 minutes before meals) and externally - Rozaliak cream (2 times a day). Patents of this group were under the close supervision of a cardiologist. The period of observation after treatment was 12 months.  During this period the relapses in the group of study were not observed, while in the control group - relapses were detected already in the third month of observation. At the same time, a substantial reduction of erythema in patients with rosacea were not revealed. Thus, this study suggests that beta-blockers and Rozaliak are effective choice for the treatment of torpid relapsing forms of Rosacea on erythematous stage of disease, as well as for stable and long-term clinical remission.
authors: Tbilisi State Medical University, Department of Dermatovenereology, Tbilisi, Georgia.
authors: N V
authors: NV
authors: Tsiskarishvili
authors: A
authors: A
authors: Katsitadze
authors: Ts
authors: Ts
authors: Tsiskarishvili
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004890:Erythema / Q000188:drug therapy; D005260:Female; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D009824:Ointments / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012008:Recurrence; D012393:Rosacea / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000900:Anti-Bacterial Agents; D006633:Histamine Antagonists; D009824:Ointments; D008795:Metronidazole; D011433:Propranolol